Probiotics, prebiotics, synbiotics: ecological treatment for inflammatory bowel disease?

Marteau, P.
December 2006
Gut;Dec2006, Vol. 55 Issue 12, p1692
Academic Journal
The author reflects on the ecological treatment for inflammatory bowel disease of probiotics, prebiotics, and synbiotics. An overview of the several studies conducted on probiotics, prebiotics, and synbiotics are offered. He views that these researches will offer a large field of potential applications for clinical and preclinical research, and will also lead to new treatments. He mentions that in patient with ulcerative colitis the ecological treatment may be beneficial.


Related Articles

  • Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Thomas, Saskia; Baumgart, Daniel // Inflammopharmacology;Feb2012, Vol. 20 Issue 1, p1 

    Crohn's disease and ulcerative colitis are two chronic inflammatory bowel diseases. Current biologic therapies are limited to blocking tumor necrosis factor alpha. However, some patients are primary non-responders, experience a loss of response, intolerance or side effects defining the urgent...

  • A Case of "Cap Polyposis"-Like Lesion Associated With Ulcerative Colitis: Is This a Case of Cap Polyposis? Tamura, Satoru; Onishi, Saburo; Ohkawauchi, Kohji; Miyamoto, Takako; Ueda, Hiroshi // American Journal of Gastroenterology;Nov2000, Vol. 95 Issue 11, p3311 

    Describes a case of a cap polyposis-like lesion associated with ulcerative colitis in a 48-year-old female referred for evaluation of diarrhea and abdominal pain. Medical history of the patient; Medications received; Mechanism underlying cap polyposis-like lesion.

  • The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity. Clara, Ian; Lix, Lisa M.; Walker, John R.; Graff, Lesley A.; Miller, Norine; Rogala, Linda; Rawsthorne, Patricia; Bernstein, Charles N. // American Journal of Gastroenterology;Jul2009, Vol. 104 Issue 7, p1754 

    OBJECTIVES:A single-item indicator of disease activity over an extended period of time, the Manitoba Inflammatory Bowel Disease Index (MIBDI), is introduced and compared against several standard measures for assessing activity in patients with Crohn's disease (CD) and ulcerative colitis...

  • The Month of Birth is Linked to the Risk of Crohn's Disease in the Israeli Population. Chowers, Yehuda; Odes, Shmuel; Bujanover, Yoram; Eliakim, Rami; Bar Meir, Simon; Avidan, Benjamin // American Journal of Gastroenterology;Oct2004, Vol. 99 Issue 10, p1974 

    OBJECTIVE: The main objective is to study whether the month of birth is associated with the development of Crohn's disease (CD) in the Israeli Jewish population.BACKGROUND: It was suggested that perinatal exposure to infectious agents may have a role in the pathogenesis of CD. Due to the...

  • CRP Correlates with Clinical Score in Ulcerative Colitis but Not in Crohn’s Disease. Alexander Rodgers; Adrian Cummins // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2063 

    Abstract  The aim of this study was to prospectively evaluate the correlation between clinical scoring systems and C-reactive protein (CRP) in inflammatory bowel disease. The modified Harvey-Bradshaw index was used in 40 patients (58 assessments) with Crohn’s...

  • Alleviation of Experimental Ulcerative Colitis with the Synthetic Peptide, F2A4-K-NS (Fibratide). Xinhua Lin; Paul Zamora; Kazu Takahashi; Yi Lui // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2054 

    Abstract  Recombinant fibroblast growth factors (FGFs) maintain the integrity of the gut epithelium and reduce mucosal injury in experimental inflammatory bowel disease (IBD). Chemically synthesized FGF mimetics could potentially extend the utility of FGFs by tailoring them for...

  • Esophageal Hyperalgesia in Patients With Ulcerative Colitis: Role of Experimental Stress. Galeazzi, Francesca; Lucà, Maria Grazia; Lanaro, Debora; D'Incà, Renata; D'Odorico, Anna; Sturniolo, Giacomo Carlo; Mastropaolo, Gaetano // American Journal of Gastroenterology;Sep2001, Vol. 96 Issue 9, p2590 

    OBJECTIVES: Intestinal inflammation is associated with enteric nervous system alterations, at both inflamed and non-inflamed sites. The perception of stimuli from the GI tract is enhanced during inflammatory conditions, but it is unknown whether visceral hypersensitivity is limited to the...

  • British gastroenterologists' care profile for patients with inflammatory bowel disease: the need for a patients' charter. Probert, C.S.J.; Jayanthi, V.; Mayberry, J. F. // Journal of the Royal Society of Medicine;May1993, Vol. 86 Issue 5, p271 

    The follow-up of patients with inflammatory bowel disease (IBD) was investigated using a postal questionnaire sent to 359 members of the British Society of Gastroenterology (BSG), of whom 235 replied. Of patients with IBD, 96% were weighed on each outpatient clinic review and over 60% had their...

  • Acute Tubular Injury Associated with Mesalazine Therapy in an Adolescent Girl with Inflammatory Bowel Disease. Nuray Uslu; Hulya Demir; Inci Saltik-Temizel; Rezan Topaloğlu; Figen Gürakan; Aysel Yüce // Digestive Diseases & Sciences;Nov2007, Vol. 52 Issue 11, p2926 

    Abstract  Mesalazine is a first-line drug in pediatric inflammatory bowel disease, and is effective as primary treatment and maintenance therapy. It’s usually well tolerated, but various side effects have been described. A 15-year-old female with ulcerative colitis...


Read the Article


Sign out of this library

Other Topics